Should Women Between the Ages of 25 and 30 Get Tested for HPV?

Reyhan Gündüz; Elif Ağaçayak; Özlem Polat Bozbay; Ulaş Alabalık; Mehmet Sait İçen; Talip  Gül

doi:10.54614/eurjther.2021.0108

Authors

Reyhan Gündüz Department of Obstetrics and Gynecology, Dicle University, Faculty of Medicine, Diyarbakır, Turkey https://orcid.org/0000-0001-8468-7038
Elif Ağaçayak Department of Obstetrics and Gynecology, Dicle University, Faculty of Medicine, Diyarbakır, Turkey https://orcid.org/0000-0002-4215-1371
Özlem Polat Bozbay Department of Obstetrics and Gynecology, Dicle University, Faculty of Medicine, Diyarbakır, Turkey https://orcid.org/0000-0002-4215-1371
Ulaş Alabalık Department of Pathology, Dicle University, Faculty of Medicine, Diyarbakır, Turkey https://orcid.org/0000-0003-4551-8439
Mehmet Sait İçen Department of Obstetrics and Gynecology, Dicle University, Faculty of Medicine, Diyarbakır, Turkey https://orcid.org/0000-0001-7982-1407
Talip Gül Department of Obstetrics and Gynecology, Dicle University, Faculty of Medicine, Diyarbakır, Turkey https://orcid.org/0000-0002-6941-6851

DOI:

https://doi.org/10.54614/eurjther.2021.0108

Keywords:

Cervical cancer, human papillomavirus test, Papanicolaou smear test, screening program, young women

Abstract

Objectives: The aim of this study is to discuss whether performing the human papillomavirus test on women aged 25-30 in Turkey has any effect on preventing cervical cancer. It is aimed to reevaluate the screening program.

Methods: A total of 400 patients between the ages of 25-30 who had the Papanicolaou smear and the human papillomavirus test were included in our study. Pap smear and the human papillomavirus test were performed again on the patients with a positive human papillomavirus test for high-risk types in accordance with the screening program. Demographical and clinical characteristics of the patients were recorded. The incidence of human papillomavirus test positivity with a high risk among patients aged 25-30, regression, and persistence ratios were calculated.

Results: The incidence of human papillomavirus test positivity with a high risk among patients aged 25 to 30 was found to be 7%. Human papillomavirus persistence ratio was 17.6% and the regression ratio was 82.4%. Among patients with a positive high-risk human papillomavirus test between the ages of 25 and 30, human papillomavirus 16 was found in 47.1% of the patients. For one of our patients with a persistent human papillomavirus 16 positivity, conization was performed after the cervical biopsy.

Conclusion: We believe that human papillomavirus, which plays an important role in the etiology of cervical cancer, should be screened from the age of 25. This way, we can catch and treat precursor lesions of cervical cancer at earlier ages and lower the incidence and mortality of cervical cancer

Metrics

Metrics Loading ...

References

Bruni L, Barrionuevo-Rosas L, Albero G, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World: Summary Report. Available at: http: //www .hpvc entre .net/ stati stics /repo rts/X WX.pd f. Accessed April 13, 2017.

Loaeza-Loaeza J, Illades-Aguiar B, Moral-Hernández OD, Castro-Coronel Y, Leyva-Vázquez MA, Dircio-Maldonado R, et al. The CpG island methylator phenotype increases the risk of high-grade squamous intraepithelial lesions and cervical cancer. Clin Epigenetics. 2022;14(1):4.

Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, et al. Final efficacy, immunogenicity, and safety analyses of a ninevalent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143-2159.

Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7(1):38.

Basu P, Mittal S, Bhadra Vale D, Chami Kharaji Y. Secondary prevention of cervical cancer. Best Pract Res Clin Obstet Gynaecol. 2018;47:73-85.

Yıldırım D, Gökaslan H. Serviks kanseri taramasında HPV DNA testinin yeri. Türk Jinekol Onkol Derg. 2015;1:1-6.

Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147-172.

Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin Number 131: Screening for cervical cancer. Obstet Gynecol. 2012;120:1222-1238.

Gökgöz N, Aktaş D. Kadınların Serviks Kanseri ve Pap Smear Testi Yaptırma Durumlarına Yönelik Farkındalık Düzeylerinin Belirlenmesi. Yıldırım Beyazıt Univ Sağlık Bilimleri Fak Hemşirelik Derg. 2015;3:11-23.

Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136(2):189-197.

Kim JJ, Burger EA, Regan C, Sy S. Screening for cervical cancer in primary care: a decision analysis for the US Preventive Services Task Force. JAMA. 2018;320(7):706-714.

Einstein MH, Burk RD. Persistent human papillomavirus Infection: definitions and clinical implications. Papillomavirus Rep. 2001;12:119-123.

Schiffman M, Boyle S, Raine-Bennett T, et al. The role of human papillomavirus Genotyping in cervical cancer screening: a large-scale evaluation of cobas HPV test. Cancer Epidemiol Biomarkers Prev. 2015;24(9):1304-1310.

Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114-2119.

Veldhuijzen NJ, Berkhof J, Gillio-Tos A, et al. The age distribution of type-specific high-risk human papillomavirus incidence in two population-based screening trials. Cancer Epidemiol Biomarkers Prev. 2015;24(1):111-118.

Castle PE, Stoler MH, Wright Jr TC, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12(9):880-890.

Conde-Ferraez L, Suarez Allen RE, Carrillo Martinez JR, Ayora-Talavera G, Gonzalez-Losa Mdel R. Factors associated with cervical cancer screening amongst women of reproductive age from Yucatan, Mexico. Asian Pac J Cancer Prev. 2012;13(9):4719-4724.

Sasieni P, Castanon A. Dramatic increase in cervical cancer registrations in young women in 2009 in England unlikely to be due to the new policy not to screen women aged 20-24. J Med Screen. 2012;19(3):127-132.

You W, Li S, Du R, Zheng J, Shen A. Epidemiological study of highrisk human papillomavirus infection in subjects with abnormal cytological findings in cervical cancer screening. Exp Ther Med. 2018;15(1):412-418.

Findik S, Findik S, Abuoğlu S, Cihan FG, Ilter H, Iyisoy MS. Human papillomavirus (HPV) subtypes and their relationships with cervical smear results in cervical cancer screening: a community-based study from the central Anatolia region of Turkey. Int J Clin Exp Pathol. 2019;12(4):1391-1398.

Felix JC, Lacey MJ, Miller JD, Lenhart GM, Spitzer M, Kulkarni R. The clinical and economic benefits of co-testing Versus primary HPV testing for cervical cancer screening: A modeling analysis. J Womens Health (Larchmt). 2016;25(6):606-616.

Bhatla N, Singhal S. Primary HPV screening for cervical cancer. Best Pract Res Clin Obstet Gynaecol. 2020;65:98-108.